Allied Health & Imaging · Independent exam preparation
SBB(ASCP): Specialist Blood Banking Decisions Study Guide
Practise component selection, complex antibody investigations, transfusion reaction analysis, and laboratory leadership with focused SBB(ASCP) cases and recall drills.
By CertMedbry · Updated 1 November 2026
Choose appropriate components, resolve difficult serologic findings, distinguish transfusion complications, and evaluate laboratory quality decisions. This guide develops specialist reasoning across the six SBB domains, including laboratory administration. Its 60 concepts are selective: the complete official ASCP BOC outline defines the full examination scope.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which credential and pathway does this guide cover?
This guide selects SBB(ASCP), the Specialist in Blood Banking credential. The shared issuer document also covers SBB(ASCPi) and the Scientist in Blood Banking credentials BB(ASCP) and BB(ASCPi). Those labels should not be treated as interchangeable. This guide uses the SBB percentages and includes laboratory administration, which the outline specifically identifies as SBB-only content.
ASCP BOC BB/SBB Examination Content Guideline — December 5, 2025
How many questions are given, and how long is the examination?
The December 5, 2025 guideline describes 100 questions in 2 hours 30 minutes. It does not identify a separate scored-question count or pretest-question count.
ASCP BOC BB/SBB Examination Content Guideline — December 5, 2025
What delivery method and question styles are described?
The guideline specifies computer adaptive testing and multiple-choice questions with one best answer. Questions may assess theoretical application, calculations, correlation of laboratory findings with disease, laboratory procedures, and quality assurance. The 20 questions here are independent four-option learning drills; they do not reproduce adaptive delivery or predict a passing result.
ASCP BOC BB/SBB Examination Content Guideline — December 5, 2025
Which blueprint revision applies to these materials?
These materials use the official guideline revised December 5, 2025. No separate effective date is stated. The September 25, 2025 official copy is historical relative to that revision.
ASCP BOC BB/SBB Examination Content Guideline — December 5, 2025 · ASCP BOC BB/SBB Examination Content Guideline — September 25, 2025
How is the SBB blueprint weighted?
The published ranges are Blood Products 10–15%; Blood Group Systems 15–20%; Immunology and Physiology 15–25%; Serologic and Molecular Testing 20–25%; Transfusion Practice 15–20%; and Laboratory Operations 10–15%. The guide allocates 8, 10, 12, 14, 10, and 6 concepts respectively. Questions and flashcards each allocate 3, 3, 4, 5, 3, and 2 items respectively.
ASCP BOC BB/SBB Examination Content Guideline — December 5, 2025
Which jurisdiction governs regulatory questions?
The outline specifies U.S. regulatory sources, including FDA, CLIA, and AABB. It separately states that donor-eligibility examination questions use regulations current as of June 2023. That is an examination convention, not a claim that clinical donor rules remained unchanged afterward. Canadian and Australian references here support general mechanisms; their local operational requirements are not substituted for U.S. examination rules.
ASCP BOC BB/SBB Examination Content Guideline — December 5, 2025
Does this guide cover the complete examination scope?
No. The official outline defines the complete scope, including topics outside these 60 selected concepts and outside a candidate's usual job. Extend study to every listed topic, including less common blood groups, donor procedures, specialized methods, instrumentation, coagulation, transplantation, and SBB administration. Laboratory results and reference ranges are provided in conventional and SI units according to the guideline.
ASCP BOC BB/SBB Examination Content Guideline — December 5, 2025 · ASCP BOC Content Guidelines & Reading Lists
Prepared for Specialist in Blood Banking, SBB(ASCP), with emphasis on integrating laboratory findings, clinical mechanisms, and operational judgment. These independently authored learning materials are not official ASCP examination items.
Outline used: ASCP BOC BB/SBB Examination Content Guideline, revised December 5, 2025; no separate effective date is stated. The workbook label maps directly to SBB(ASCP). The shared document also lists BB and international credentials; the domain percentages below are specifically for SBB. This selective guide does not replace the complete official outline.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Blood Products10–15%
1.Which component replaces the patient's missing blood function?
Component selection begins with the physiologic deficit. Red cells increase oxygen-carrying capacity, platelets support primary hemostasis, plasma supplies multiple soluble coagulation factors, and cryoprecipitate provides concentrated fibrinogen with other proteins. These products are not interchangeable simply because each originates from donated blood. Connect the patient's bleeding pattern, laboratory findings, and circulatory status to the needed function before considering product availability or modification. This prevents unnecessary volume and irrelevant component exposure.
Apply it
A patient has ongoing bleeding, markedly reduced fibrinogen, and an adequate platelet count. Identify fibrinogen replacement as the component goal, then assess the locally available replacement product rather than automatically ordering platelets for all bleeding.
Common pitfall: A low hemoglobin does not establish the cause of bleeding. Red cells can restore oxygen delivery while leaving a fibrinogen or platelet defect untreated.
Circular of Information for the Use of Human Blood and Blood Components
2.How does leukocyte reduction change transfusion risk?
Leukocyte reduction removes most donor white cells from a component. This reduces exposure to leukocyte antigens and leukocyte-associated mediators, helping reduce febrile reactions, HLA alloimmunization, and transmission risk from cell-associated cytomegalovirus. It does not remove every leukocyte or address every infectious mechanism. Most importantly, it does not reliably prevent donor T-cell proliferation responsible for transfusion-associated graft-versus-host disease. Match leukocyte reduction to its specific risk-reduction purpose rather than treating it as universal component sterilization.
Apply it
An immunocompromised patient's order specifies irradiation, but the available red-cell unit is labeled only leukocyte reduced. Recognize that its white-cell reduction does not satisfy the separate requirement to inactivate proliferating donor T lymphocytes.
Common pitfall: Leukocyte reduction and irradiation solve different problems. A reduced leukocyte count does not establish that remaining donor T cells cannot engraft and proliferate.
Circular of Information for the Use of Human Blood and Blood Components · Australian Red Cross Lifeblood — Irradiated components
3.Why are selected cellular components irradiated?
Irradiation damages donor T-lymphocyte DNA so those cells cannot proliferate in a susceptible recipient. The target complication is transfusion-associated graft-versus-host disease, in which viable donor lymphocytes attack recipient tissues. Cellular components can contain these lymphocytes even after leukocyte reduction. Irradiation therefore represents a functional treatment of residual lymphocytes, not their physical removal. Its necessity depends on the recipient and donation circumstances, and its effects on component quality and expiration must also be considered.
Apply it
A recipient with an established irradiation indication requires red cells. Select a unit with documented irradiation rather than relying on a leukocyte-reduced label, and verify that the treated unit remains within its assigned expiration.
Common pitfall: Irradiation does not replace washing for plasma-protein reactions or make a component free of bacteria. Its protective mechanism specifically concerns donor lymphocyte proliferation.
4.When does washing address the relevant component risk?
Washing removes much of the residual plasma and soluble substances surrounding cellular components. It is useful when reducing plasma exposure is the therapeutic objective, particularly in selected patients with severe recurrent allergic reactions. Washing does not alter the donor red-cell antigen profile or eliminate the need for compatible blood. Because processing can cause cell loss and may shorten usable storage, its benefit must be linked to a specific patient problem rather than ordered routinely.
Apply it
A patient has recurrent severe allergic reactions despite an appropriate evaluation and preventive plan. When plasma reduction is indicated, choose a washed cellular component while retaining all required antigen-negative, compatibility, and irradiation specifications.
Common pitfall: Choosing washed cells for an alloantibody does not remove the target antigen. Washing reduces surrounding plasma; it does not convert antigen-positive cells into compatible cells.
Circular of Information for the Use of Human Blood and Blood Components
5.What makes cryoprecipitate useful for fibrinogen replacement?
Cryoprecipitate contains the cold-insoluble fraction recovered during controlled thawing of plasma. It supplies fibrinogen and also contains factor VIII, von Willebrand factor, factor XIII, and fibronectin. Its concentrated fibrinogen content makes it relevant when fibrinogen replacement is needed without the larger plasma volume required to deliver an equivalent amount. Product selection should follow the documented deficiency and available alternatives; the presence of several proteins does not make cryoprecipitate a universal factor-replacement product.
Apply it
A bleeding patient has low fibrinogen and significant volume constraints. Explain why a concentrated fibrinogen-containing product addresses the identified deficit more directly than giving plasma solely to increase fibrinogen concentration in the circulation.
Common pitfall: Cryoprecipitate is not equivalent to plasma for broad factor replacement. Do not infer that every coagulation factor is supplied adequately because several proteins are concentrated.
6.How do storage conditions affect red-cell metabolism and extracellular potassium?
During refrigerated storage, 2,3-DPG declines as storage conditions become acidic. Depletion increases hemoglobin's oxygen affinity and initially reduces oxygen unloading. ATP supports membrane integrity and cell survival; glucose and adenine in preservation systems help sustain ATP, but ATP preservation does not establish that 2,3-DPG is also preserved. Experimental alkaline storage demonstrated that maintaining both depends on pH and phosphate availability. Potassium also accumulates outside stored red cells, and irradiation accelerates potassium leakage. Component processing, storage duration, time since irradiation, and assigned expiration therefore describe different aspects of product suitability.
Apply it
In a hypothetical comparison, one preservation system maintains ATP while measured 2,3-DPG falls sharply. Interpret this as preservation of an energy-related measure without equivalent preservation of oxygen-unloading physiology. Separately, an irradiated unit with elevated supernatant potassium requires assessment of the recipient's potassium exposure, especially during rapid transfusion.
Common pitfall: ATP, 2,3-DPG, and extracellular potassium measure different processes. A favorable result for one does not establish that the others are unchanged or that every recipient faces the same risk.
Alkaline CPD and the preservation of RBC 2,3-DPG - PubMed · Circular of Information for the Use of Human Blood and Blood Components · Australian Red Cross Lifeblood — Irradiated components
7.How should component quality-control measurements be interpreted?
Component QC tests whether processing consistently produces the intended product. Platelet yield is calculated from platelet concentration multiplied by component volume; concentration alone does not establish the total dose. Other measurements answer separate questions: residual leukocyte count assesses leukocyte-reduction performance, platelet pH assesses an aspect of storage quality, and red-cell hemolysis assesses cell damage. Apply the product's specified sampling plan and acceptance criteria to each measurement. Passing one characteristic does not compensate for failure of another, and a process-QC failure requires investigation of the affected production scope.
Apply it
A hypothetical platelet product has volume 0.25 L and platelet concentration 1.0 × 10^12/L, giving a yield of 2.5 × 10^11 platelets. If the stated product specification requires at least 3.0 × 10^11, it fails yield even when residual leukocytes and pH meet their separate criteria. Investigate sampling, measurement, and processing before deciding disposition and the extent of the problem.
Common pitfall: The example's acceptance limit is an explicit hypothetical specification, not a universal rule for all platelet products. Always distinguish concentration, total content, sampling-plan compliance, and individual-product disposition.
ASCP BOC BB/SBB Examination Content Guideline — December 5, 2025 · Circular of Information for the Use of Human Blood and Blood Components
8.Why must donor qualification, testing, and traceability work together?
Donor qualification assesses current health and relevant history to protect the donor and recipient. Infectious-disease testing addresses particular markers within assay and infection-timing limitations; a negative result does not override an adverse health assessment. Traceability connects the donation, its derived components, testing, processing, and ultimate disposition. This linkage permits targeted investigation when later information changes a donation's safety assessment. Qualification, testing, and traceability are complementary safeguards rather than interchangeable evidence of suitability.
Apply it
A prospective donor reports fever and malaise on the collection day and argues that negative testing from a previous donation proves suitability. Do not proceed with collection: current illness prevents establishing acceptable health for donation, and previous testing cannot assess the present episode. Document the finding and complete the donor-health assessment before considering a future donation. If relevant illness is instead reported after collection, use the donation identifier to locate every derivative and initiate the applicable hold and investigation.
Common pitfall: A previous successful donation or negative infectious-disease result does not establish present qualification. Accurate testing also cannot compensate for an identity break between a donor, specimen, and component.
Circular of Information for the Use of Human Blood and Blood Components · ASCP BOC BB/SBB Examination Content Guideline — December 5, 2025
Blood Group Systems15–20%
9.How does ABO inheritance produce the major phenotypes?
ABO inheritance determines enzymes that modify precursor carbohydrate structures on red cells. A and B alleles can both be expressed, producing the AB phenotype, whereas common O alleles do not produce a functional A- or B-modifying enzyme. Phenotype therefore reflects antigen expression, not simply the presence of an alphabetic label in a family history. Distinguish inherited genotype from the observed reaction pattern, especially when an unusual subgroup or clinical circumstance makes routine expression incomplete.
Apply it
A parent with genotype AO and a parent with genotype BO ask whether a group O child is possible. Each can transmit O, so an OO child is genetically possible without invoking an unusual inheritance mechanism.
Common pitfall: Group A does not uniquely identify genotype AA. Treating phenotype as genotype can produce false exclusions when interpreting family inheritance or investigating unexpected typing results.
10.Why does ABO incompatibility reverse direction between red cells and plasma?
For red-cell transfusion, the major question is whether recipient antibodies recognize donor red-cell antigens. For plasma transfusion, the major question is whether donor antibodies recognize recipient red cells. Group O red cells lack A and B antigens, but group O plasma commonly contains both anti-A and anti-B. Group AB plasma lacks those expected antibodies. Compatibility must therefore be reasoned from the material being transfused rather than transferred unchanged between red-cell and plasma selection tables.
Apply it
A group A recipient needs plasma, and group O plasma is proposed because group O red cells are familiar emergency products. Identify donor anti-A as the relevant concern and select plasma compatible with the recipient's red cells.
Common pitfall: The phrase universal donor is incomplete without naming the component. ABO advantages for red cells do not establish equivalent compatibility for the donor's plasma.
Australian Red Cross Lifeblood — ABO · Australian Red Cross Lifeblood — Component compatibility
11.When can a weak D result support RhD-positive management?
A serologic weak D result describes reduced or method-dependent D reactivity; it does not specify the underlying RHD variant. Genotype-confirmed weak D types 1, 2, and 3 can be managed as RhD positive under the joint statement for pregnant women and other females of childbearing potential. The decisive information is the molecular type. Extending that conclusion to every weak D phenotype ignores variants with different alloimmunization implications and defeats the purpose of genotyping.
Apply it
A pregnant patient has discrepant D typing across methods. RHD genotyping identifies weak D type 2. Apply the genotype-specific recommendation rather than automatically assigning the same management used for an unresolved weak D result.
Common pitfall: Weak serologic reactivity is not a genotype. The management supported for weak D types 1, 2, and 3 should not be generalized to all variants.
Joint Statement on RHD Genotyping for Pregnant Women and Other Females of Childbearing Potential
12.Why can an apparently D-positive person still require RHD investigation?
D expression varies in amount and antigenic composition. Some variants alter epitopes rather than merely reducing the quantity of an otherwise typical D antigen, so a positive serologic reaction alone cannot resolve every clinically important variant. RHD genotyping can clarify a discrepant phenotype and support appropriate prevention or transfusion decisions. Interpretation must remain variant specific: the established reassurance for weak D types 1, 2, and 3 is not proof that every D-reactive individual has the same alloimmunization risk.
Apply it
A patient historically labeled D positive shows inconsistent reactions with different D reagents during pregnancy testing. Investigate the discrepancy with an appropriate molecular strategy instead of using the strongest single reaction as definitive classification.
Common pitfall: Greater reaction strength does not necessarily mean a complete antigen structure. Quantitative weakness and qualitative epitope variation require different reasoning about potential anti-D formation.
Joint Statement on RHD Genotyping for Pregnant Women and Other Females of Childbearing Potential
13.Why can anti-K cause severe fetal anemia with limited reticulocytosis?
Anti-K can injure the fetal erythroid system through more than destruction of circulating red cells. Kell antigens are expressed on erythroid progenitors, and anti-K can inhibit development of Kell-positive progenitor cells. Reduced red-cell production therefore contributes to anemia and may blunt the expected reticulocyte response. This distinguishes an important Kell mechanism from a model based exclusively on peripheral hemolysis. Interpret fetal anemia using both destruction and production, rather than requiring vigorous marrow compensation.
Apply it
A fetus exposed to maternal anti-K develops significant anemia without a proportionate reticulocyte increase. Explain how inhibition of erythroid progenitors accounts for the pattern instead of dismissing the antibody because classic hemolysis markers appear less striking.
Common pitfall: A modest reticulocyte response does not exclude severe alloimmune fetal anemia. Anti-K can suppress the very progenitors needed to produce a compensatory response.
14.Why does an undetectable historical alloantibody still matter?
Some clinically significant red-cell alloantibodies, classically including Kidd antibodies, may decline below the detection limit of routine screening. Their disappearance from a current sample does not erase immune memory. Subsequent antigen exposure can provoke a rapid anamnestic response and delayed hemolysis. A documented antibody history therefore remains relevant to antigen-negative selection and compatibility testing. Distinguish a negative present-day assay from evidence that the patient has never been sensitized to the antigen.
Apply it
A patient previously had anti-Jka, but today's antibody screen is negative. Preserve the historical specificity in the transfusion plan and select appropriate antigen-negative red cells rather than treating the patient as having no significant antibody history.
Common pitfall: A negative screen measures current detectability, not lifetime immunologic history. Removing an antibody alert because the latest sample is nonreactive can permit hazardous re-exposure.
Canadian Blood Services — Pre-transfusion testing · Australian Red Cross Lifeblood — Delayed haemolytic transfusion reactions
15.How does antigen expression differ from a simple inherited label?
A blood-group phenotype is the observable antigen pattern under the conditions tested. Genetic inheritance is essential, but biochemical expression and the cellular environment also matter. The Lewis system illustrates the distinction because soluble Lewis substances in plasma adsorb onto red-cell membranes. Experimental incubation of antigen-negative cells with antigen-containing plasma can confer the corresponding serologic reactivity. Consequently, Lewis phenotype should be interpreted as an expression result rather than an infallible declaration of the red cell's own synthetic activity.
Apply it
A Lewis typing result differs from a previous record while ABO and identity checks agree. Consider altered expression and adsorption biology before concluding that the patient record must represent a different inherited red-cell population.
Common pitfall: Not every red-cell antigen is an integral membrane product synthesized by the erythrocyte. Applying one biochemical model to every blood-group system creates misleading interpretations.
Adsorption of Lec and Led from plasma onto red blood cells - PubMed
16.Why do MNS and Duffy investigations require attention to reagent treatment?
An antibody investigation depends on which antigens remain available on the reagent cells. Ficin modifies the membrane: Rh, Kidd, Lewis, and some other antibody reactions are commonly enhanced, whereas reactions involving enzyme-sensitive MNS and Duffy targets can be diminished or abolished. A nonreactive treated-cell result therefore cannot independently exclude an antibody when its target has been removed. Compare untreated and treated panels as complementary experiments. The critical distinction is between absence of antibody binding and absence of the antigen needed to demonstrate binding.
Apply it
An untreated panel suggests anti-Fya, but the ficin-treated panel is nonreactive. Interpret destruction of the target antigen as an explanation and continue identification with appropriate untreated cells rather than excluding the specificity.
Common pitfall: Enhanced sensitivity is not universal sensitivity. An enzyme panel can improve detection of some antibodies while making other clinically significant specificities impossible to assess reliably.
17.How does antigen prevalence guide the search for compatible units?
Antigen prevalence determines how often an antigen-negative donor is expected, whereas immunogenicity concerns the likelihood of an immune response after exposure. These are different properties. If 20% of a relevant donor population lacks an antigen, approximately one in five units is expected to be negative, but actual sampling varies. For multiple requirements, multiplying negative frequencies is appropriate only when independence is justified. Use population-relevant frequencies and recognize antigen linkage or ancestry-related differences before forecasting inventory needs.
Apply it
Two required antigen-negative phenotypes occur at frequencies of 0.20 and 0.50 and are explicitly independent in the relevant donor pool. Their combined frequency is 0.10, giving an expectation of about ten screened units per suitable unit.
Common pitfall: Expected yield is not a guarantee. Multiplying frequencies without checking independence or the relevant donor population can seriously underestimate the search needed for compatible blood.
ASCP BOC BB/SBB Examination Content Guideline — December 5, 2025
18.How are platelet refractoriness and possible HLA or HPA alloimmunity investigated?
Obtain a pretransfusion platelet count and a posttransfusion count 10–60 minutes after completion, recording the platelet dose and body surface area. Corrected count increment, or CCI, equals platelet increment per microliter × body surface area in m² ÷ platelet dose expressed in units of 10^11. Use counts from at least two sequential transfusions to establish a repeated inadequate response. A practical criterion is CCI below 5,000 on both occasions; thresholds vary, and some protocols use below 7,500. Repeatedly low early CCIs support investigation but do not independently prove alloimmunity. Assess bleeding, sepsis, consumption, sequestration, product factors, and ABO mismatch alongside HLA class I and HPA antibodies. Demonstrated specificity can guide HLA-selected, HPA-selected, antibody-compatible, or platelet-crossmatch-compatible products.
Apply it
A patient's count rises from 10,000/µL to 15,000/µL, equivalent to 10 to 15 × 10^9/L, 30 minutes after a dose of 3.0 × 10^11 platelets. With body surface area 1.8 m², CCI = 5,000 × 1.8 ÷ 3.0 = 3,000. A second adequately documented transfusion also gives CCI below 5,000, meeting the selected repeated-low-increment criterion. Investigate nonimmune contributors and HLA/HPA antibodies. If clinically relevant HLA antibodies are demonstrated, trial appropriately selected or crossmatch-compatible platelets and repeat the timed CCI to assess response.
Common pitfall: Enter the dose as 3.0 when the product contains 3.0 × 10^11 platelets; mixing platelet-count units changes the result by orders of magnitude. Neither one poor increment nor an HLA antibody result alone establishes alloimmune refractoriness.
Immunology and Physiology15–25%
19.How do IgG and IgM properties influence transfusion problems?
Immunoglobulin structure influences where an antibody acts and how it is detected. IgM's multivalent structure supports direct agglutination and efficient complement activation when appropriate antigen spacing is present. IgG commonly requires an antiglobulin method to reveal red-cell sensitization and can cross the placenta. Class alone does not determine clinical significance: thermal activity, antigen specificity, complement effects, and the clinical setting also matter. Use immunoglobulin properties to explain a pattern rather than treating class as a complete diagnosis.
Apply it
A maternal red-cell antibody is implicated in fetal disease. Explain why placental transfer supports an IgG-mediated mechanism, then assess antigen specificity and fetal antigen status rather than assuming every maternal antibody carries the same fetal risk.
Common pitfall: Cold reactivity, IgM class, and harmlessness are not interchangeable terms. Clinical interpretation requires the antibody's actual behavior and specificity, not a single generalization about immunoglobulin class.
Circular of Information for the Use of Human Blood and Blood Components · Canadian Blood Services — Transfusion reactions
20.Why is a secondary immune response important after transfusion?
Initial antigen exposure can establish immune memory even after circulating antibody becomes difficult to detect. Re-exposure may then trigger a faster antibody response than the original exposure. In transfusion, this can produce delayed destruction of antigen-positive donor red cells after apparently acceptable pretransfusion testing. The sequence of previous sensitization, current antigen exposure, and subsequent antibody reappearance is the discriminating clue. A current negative screen does not exclude the possibility of an anamnestic response to a historical antigen.
Apply it
Several days after transfusion, a patient's hemoglobin falls and a previously documented alloantibody reappears. Link the timing to immune memory and investigate donor antigen exposure, rather than assuming the negative pretransfusion screen excluded immune hemolysis.
Common pitfall: A delayed reaction need not reflect newly created immune memory. An old, undetectable antibody can return rapidly after re-exposure and damage the transfused cells.
Australian Red Cross Lifeblood — Delayed haemolytic transfusion reactions
21.Why does a positive DAT not establish immune hemolysis?
The direct antiglobulin test detects immunoglobulin and/or complement associated with the patient's red cells, depending on the reagent used. It demonstrates sensitization, not the rate of red-cell destruction. Establishing immune hemolysis requires compatible clinical and laboratory evidence, such as a falling hemoglobin with biochemical evidence of increased red-cell breakdown. A positive DAT can occur without clinically important hemolysis. Interpret the test alongside transfusion history, medications, other serologic findings, and the patient's overall course.
Apply it
A patient has a newly positive DAT but stable hemoglobin and no biochemical evidence of hemolysis. Investigate the coating and clinical context without labeling the patient as having active hemolytic anemia on the DAT alone.
Common pitfall: Reaction strength does not directly measure hemolysis severity. Strong sensitization can occur without major destruction, while clinically important hemolysis may require interpretation beyond a single DAT result.
University of Toronto LearnSerology — Eluate Testing · Canadian Blood Services — Transfusion reactions
22.How can complement change the pattern of red-cell injury?
Complement activation can amplify antibody-mediated red-cell injury. Antibody binding may initiate the classical pathway, producing complement deposition and, when activation proceeds sufficiently, membrane attack and intravascular hemolysis. Cells coated with complement fragments may also be cleared without immediate membrane rupture. Consequently, a complement-positive DAT and evidence of hemolysis require interpretation together. Distinguish the initiating recognition event from downstream injury: the presence of deposited complement does not by itself prove that terminal complement-mediated lysis has occurred.
Apply it
After an incompatible transfusion, a patient develops hemoglobinemia and a complement-positive DAT. Explain how antibody-triggered complement activation can account for intravascular injury while using the full investigation to establish the implicated incompatibility and reaction mechanism.
Common pitfall: Complement coating is not synonymous with intravascular lysis. The pathway may stop before terminal membrane injury, and clearance can also occur through other mechanisms.
23.When does extracellular potassium in stored red cells become a clinical concern?
Stored red-cell supernatant contains potassium that has leaked from the cells; irradiation increases this leakage. The recipient's exposure depends on extracellular potassium concentration, the volume of supernatant delivered, and delivery rate. Rapid large-volume transfusion can deliver potassium faster than it is redistributed or cleared. Neonates and other small recipients receive a larger exposure relative to body size, while impaired renal function or pre-existing hyperkalemia adds vulnerability. This mechanism differs from 2,3-DPG depletion, which changes oxygen affinity, and ATP depletion, which compromises cellular maintenance.
Apply it
In a hypothetical case, a 3-kg infant with oliguria and recipient potassium of 5.8 mmol/L needs rapid large-volume red-cell transfusion. An available unit was irradiated several days earlier and has measured supernatant potassium of 45 mmol/L. These findings identify an immediate potassium-load concern. Arrange potassium and cardiac monitoring and a component strategy that reduces extracellular potassium, such as washing close to use when feasible, while preserving the required irradiation protection and urgent transfusion support.
Common pitfall: An in-date irradiated unit can still contain clinically relevant extracellular potassium. Washing reduces the current supernatant load, but subsequent storage permits renewed accumulation; preparation-to-use timing matters.
Circular of Information for the Use of Human Blood and Blood Components · Australian Red Cross Lifeblood — Irradiated components · Alkaline CPD and the preservation of RBC 2,3-DPG - PubMed
24.How do platelet and coagulation-factor deficits produce different treatment targets?
Hemostasis depends on platelet participation and a functioning coagulation system, so bleeding cannot be classified adequately by hemoglobin alone. Platelet number and function concern primary hemostasis; soluble factors support fibrin formation, and fibrinogen provides the substrate for that fibrin. Component therapy should address the demonstrated deficit while recognizing that severe illness may affect several mechanisms simultaneously. A laboratory abnormality becomes clinically useful when linked to bleeding, procedural risk, and the specific hemostatic function a proposed component can restore.
Apply it
A bleeding patient has an adequate platelet count but marked fibrinogen depletion. Recognize that additional platelets do not replace missing fibrinogen, and identify the appropriate factor-replacement objective while assessing other possible contributors to bleeding.
Common pitfall: An adequate platelet count does not prove normal platelet function. Conversely, a low fibrinogen concentration cannot be corrected by assuming every bleeding problem is platelet mediated.
Circular of Information for the Use of Human Blood and Blood Components · Australian Red Cross Lifeblood — Cryoprecipitate
25.How does maternal alloimmunization cause HDFN?
Hemolytic disease of the fetus and newborn requires a maternal antibody capable of reaching the fetal circulation and recognizing an antigen on fetal erythroid cells. The maternal specificity and fetal antigen status are therefore central to risk assessment. Injury may involve red-cell destruction, impaired erythropoiesis, or both, depending on the antibody. Prevention and investigation must be matched to the antigen involved; a strategy directed against D alloimmunization does not prevent disease caused by unrelated red-cell antibodies.
Apply it
A pregnant patient has anti-K and a fetus at risk of expressing K. Explain why fetal risk cannot be assessed through the mother's ABO type alone and why suppressed erythropoiesis may contribute substantially to fetal anemia.
Common pitfall: HDFN is not restricted to anti-D. Concentrating only on RhD can miss clinically important maternal antibodies against other fetal red-cell antigens and progenitor targets.
Vaughan et al. — Inhibition of erythroid progenitor cells by anti-Kell antibodies in fetal alloimmune anemia · Joint Statement on RHD Genotyping for Pregnant Women and Other Females of Childbearing Potential
26.How should a coagulation-factor assay be interpreted against its calibration curve?
A clot-based factor assay estimates the patient's functional factor activity by comparing a defined test mixture with calibrated standards. Interpretation requires the assay's validated curve, reportable range, specimen dilution, and controls. Clotting time is not itself a percentage activity, and percentages cannot be calculated by simply dividing a normal clotting time by the patient's time. A low factor result identifies reduced measured activity, but assay interference and inhibitors must be considered before equating it with an inherited quantitative deficiency.
Apply it
In a hypothetical factor VIII assay, the validated calibration table gives 30 seconds at 100% activity, 40 seconds at 50%, and 50 seconds at 25%. The patient's mixture clots at 50 seconds using the same validated dilution, controls pass, and no additional dilution correction applies. Reported activity is 25%, not 60% from dividing 30 by 50. Correlate the result with bleeding history and investigate interference or an inhibitor if the clinical or assay pattern is discordant.
Common pitfall: The calibration values in this case are hypothetical. Use the actual assay's validated relationship rather than assuming that clotting time and activity have a universal linear or reciprocal relationship.
ASCP BOC BB/SBB Examination Content Guideline — December 5, 2025
27.How should immune and nonimmune cytopenia mechanisms be separated?
A low cell count can reflect reduced production, increased destruction, consumption, sequestration, or dilution. An immune mechanism requires evidence supporting immune recognition rather than merely the presence of anemia or thrombocytopenia. For red cells, correlate sensitization testing with hemolysis; for platelets, distinguish antigen-specific destruction from nonimmune clinical causes such as sepsis, disseminated intravascular coagulation, bleeding, and sequestration. Production failure can coexist with increased loss. The useful classification explains the count, its trajectory, and the accompanying clinical and laboratory pattern.
Apply it
A patient with sepsis has a rapid platelet decline, active bleeding, low fibrinogen, and poor increments after platelet transfusion. These findings support a nonimmune consumptive process requiring investigation and treatment of the underlying illness and hemostatic deficits. Document timed increments, but do not diagnose HLA-mediated destruction or order HLA-selected platelets solely because the posttransfusion count is low.
Common pitfall: A cytopenia is an outcome, not a mechanism. An inadequate platelet increment during severe consumption does not independently demonstrate an antiplatelet antibody, and immune and nonimmune contributors can coexist.
Platelet transfusion, alloimmunization and management of platelet refractoriness | Professional Education · Vaughan et al. — Inhibition of erythroid progenitor cells by anti-Kell antibodies in fetal alloimmune anemia
28.How do major and minor ABO mismatches differ in progenitor-cell transplantation?
In major ABO mismatch, recipient antibodies can recognize donor erythroid antigens. In minor mismatch, donor-derived antibodies or antibody-producing cells can recognize recipient red cells. Both directions may coexist in a bidirectional mismatch. This framework explains why transplant support cannot be determined from donor blood group alone. Component selection must account for recipient antibodies, donor antibodies, changing erythropoiesis, and the transplant phase. The directional definition is the foundation for anticipating incompatible cells or plasma during the transition.
Apply it
A group O recipient receives progenitor cells from a group A donor. Identify recipient anti-A against donor erythroid cells as the major-mismatch direction, then assess component support using the program's phase-specific compatibility plan.
Common pitfall: A successful progenitor-cell transplant does not instantly erase recipient antibodies or residual recipient red cells. One ABO label cannot describe every compatibility concern during transition.
ANZSBT Guidelines for Transfusion and Immunohaematology Laboratory Practice — June 2025
29.How can donor passenger lymphocytes cause hemolysis after an organ transplant?
A minor ABO-mismatched solid-organ graft can carry donor lymphocytes capable of producing antibodies against recipient red cells. For example, lymphocytes accompanying a group O heart-lung graft can produce anti-A in a group A recipient. The antibody source is donor-derived lymphoid tissue; the target is the recipient's A-positive red cells. The primary heart-lung transplantation study documented hemolysis beginning 4–12 days after transplantation and recipient-incompatible ABO antibodies in serum and red-cell eluates. This is passenger-lymphocyte-mediated immune destruction, rather than an immediate change of the recipient's inherited red-cell group.
Apply it
A hypothetical group A recipient of a group O heart-lung graft develops falling hemoglobin, increased bilirubin and LDH, reduced haptoglobin, a positive DAT, and anti-A in an eluate on day 8. Donor-derived anti-A explains destruction of recipient A cells. If red-cell support is needed, group O red cells avoid the A target and must also satisfy other antibody and crossmatch requirements. Plasma selection must separately avoid antibodies against the recipient's remaining A cells.
Common pitfall: Selecting red cells solely by the recipient's original group would reintroduce the antibody target. Selecting plasma solely by the group O organ donor would introduce anti-A; analyze cells and plasma separately.
Induction of red blood cell destruction by graft-derived antibodies after minor ABO-mismatched heart and lung transplantation - PubMed · Australian Red Cross Lifeblood — Component compatibility
30.Why can citrate exposure lower ionized calcium?
Citrate prevents coagulation by binding calcium. When citrate-containing blood products or extracorporeal anticoagulant enter the circulation, the citrate load can transiently reduce ionized calcium, particularly when delivery exceeds the patient's capacity to metabolize citrate. Total calcium does not necessarily describe the biologically available fraction accurately in this setting. Symptoms and measured ionized calcium should be interpreted against the exposure rate and clinical condition. The mechanism is calcium binding, not an antibody reaction against transfused cells.
Apply it
During a citrate-anticoagulated collection procedure, a donor develops perioral tingling and ionized calcium falls. Link the findings to citrate exposure and communicate promptly with the clinical team rather than beginning a red-cell alloantibody investigation.
Common pitfall: Normal total calcium does not exclude reduced ionized calcium. The physiologically active fraction is the more direct measurement when citrate binding is the suspected mechanism.
Circular of Information for the Use of Human Blood and Blood Components
Serologic and Molecular Testing20–25%
31.How should discordant forward and reverse ABO results be approached?
Forward grouping tests red-cell antigens, whereas reverse grouping tests expected plasma antibodies. Agreement provides an internal consistency check; disagreement is a finding that requires explanation. Verify identity and technical factors, then determine whether the problem concerns antigen expression, antibody expression, mixed cell populations, or interference. Patient age, transfusion, transplantation, and clinical history can change the interpretation. Do not average conflicting reactions or choose whichever side appears stronger before understanding the discrepancy and arranging safe support.
Apply it
Forward typing appears group A, but reverse grouping lacks the expected anti-B reaction. Review the patient's age, immune status, and technical controls, then resolve the missing antibody pattern rather than changing the group from one weak result.
Common pitfall: A discrepancy does not automatically mean an unusual subgroup. Identity errors, technical problems, missing antibodies, and mixed populations should remain active possibilities during the investigation.
32.Why does specimen identity outrank an apparently plausible blood group?
A technically correct assay can produce a dangerous clinical result when the specimen belongs to someone else. Pretransfusion testing therefore depends on unambiguous patient identification, collection labeling, and reconciliation with historical information. An unexpected ABO difference is an identity signal until adequately investigated, although transfusion or transplantation may also explain some changes. Repeating the assay on the same mislabeled tube only repeats the original identity problem. Analytical reproducibility cannot establish that the sampled person is the intended recipient.
Apply it
A current specimen types group B while a reliable historical record shows group O. Investigate collection and identification and obtain an appropriately identified specimen when required, rather than repeatedly testing the original tube until its reactions seem convincing.
Common pitfall: Duplicate testing is not independent identity confirmation when both tests use the same potentially wrong specimen. Reliable collection linkage must be established separately from assay repeatability.
33.Which question is answered by the DAT versus the IAT?
The DAT asks whether the patient's red cells are already coated with detectable immunoglobulin or complement. The IAT asks whether antibodies in a tested fluid can sensitize reagent or donor red cells under the assay conditions. These are different experimental questions, even though both may use antiglobulin reagents. Choose the test according to the suspected location of antibody activity. A negative plasma investigation does not automatically negate coating already present on circulating cells, and cell coating does not identify a plasma specificity.
Apply it
A reaction investigation requires assessment of both circulating red-cell sensitization and a possible new plasma alloantibody. Use a DAT for the patient's cells and an appropriate antibody investigation for plasma rather than expecting either test to answer both questions.
Common pitfall: The shared antiglobulin reagent does not make the tests interchangeable. Their starting materials and clinical questions differ, so conclusions must remain tied to the actual assay.
FDA-hosted Package Insert — Anti-Human Globulin Anti-IgG (Rabbit) · University of Toronto LearnSerology — Eluate Testing
34.What does failure of IgG-sensitized check cells invalidate?
In a negative tube antiglobulin test, IgG-sensitized check cells should agglutinate after addition. Their reaction demonstrates that active antiglobulin reagent remains able to detect IgG-coated cells. Failure means the negative test cannot be accepted as valid. Potential causes include omitted or inactive reagent and neutralization by residual unbound globulin after inadequate washing. The check-cell result does not diagnose the patient's antibody status; it assesses whether the negative antiglobulin phase was capable of demonstrating the intended reaction.
Apply it
An antibody screen is nonreactive at the tube antiglobulin phase, but the added check cells also remain nonreactive. Repeat the affected testing after investigating procedural failure rather than reporting a valid negative screen.
Common pitfall: Check cells validate a negative tube result; they do not convert an invalid test into a negative patient finding. Their failure requires corrective testing.
FDA-hosted Package Insert — Anti-Human Globulin Anti-IgG (Rabbit)
35.How does reagent-cell selection distinguish candidate antibodies and permit dosage-sensitive exclusion?
Select cells that separate candidate antigens and retain adequate expression of each target. Anti-Jka can show dosage, so nonreactive Jk(a+b−) cells provide stronger exclusion evidence than Jk(a+b+) cells. In a hypothetical untreated IAT panel, cell 1 is E+, Jk(a+b−), reactive 2+; cell 2 is E+, Jk(a+b+), reactive 2+; cell 3 is E−, Jk(a+b−), nonreactive; cell 4 is E−, Jk(a+b−), nonreactive; and cell 5 is E+, Jk(a−b+), reactive 2+. The initial two reactive cells fit either anti-E or anti-Jka. Cell 5 demonstrates reactivity without Jka, while cells 3 and 4 provide homozygous Jka expression without E.
Apply it
Assume the hypothetical laboratory's validated exclusion procedure requires two nonreactive cells with homozygous expression for dosage-sensitive targets. Cells 3 and 4 satisfy that rule, so exclude detectable anti-Jka under these assay conditions. Their nonreactivity and cell 5's reactivity support anti-E as the explanation for this antigen contrast. Complete anti-E confirmation with the full panel and a reliable patient antigen profile; evaluate every remaining clinically significant specificity separately. These selected cells do not establish that no additional antibody exists.
Common pitfall: Nonreactivity with only Jk(a+b+) cells may miss dosage-sensitive anti-Jka. Conversely, a reactive E-positive cell that also carries Jka does not independently discriminate anti-E from anti-Jka.
36.What control makes an antibody-neutralization result interpretable?
Neutralization tests whether a soluble target can inhibit a particular antibody reaction before the sample is tested against red cells. The essential comparison is between the treated sample and a control sample exposed to the same dilution and handling without the specific neutralizing target. Loss of reactivity only in the specifically treated sample supports inhibition; loss in both samples may simply reflect dilution below detection. Residual reactivity can reveal another antibody, provided the remaining assay conditions and controls are valid.
Apply it
In a hypothetical validated neutralization experiment, both aliquots begin with identical reactive plasma. After equal dilution, the control remains reactive while the aliquot receiving the specific soluble target becomes nonreactive. This supports specific inhibition. If both aliquots become nonreactive, the experiment cannot distinguish neutralization from dilution-related loss of detection.
Common pitfall: A negative treated sample without a matched dilution control does not establish specificity. Neutralizing one reactivity also does not establish that every clinically significant antibody has been excluded.
ASCP BOC BB/SBB Examination Content Guideline — December 5, 2025
37.When is autoadsorption appropriate for a warm autoantibody investigation?
Autoadsorption uses the patient's own red cells to remove plasma autoantibody so underlying alloantibodies can be investigated. It is most informative when the cells represent the patient's antigen profile and enough suitable cells are available. Recent transfusion creates a critical limitation because donor cells may be present and can adsorb alloantibodies against donor antigens. The resulting apparently simplified plasma could then conceal the very antibody the investigation seeks. Adsorption choice must therefore incorporate transfusion history before processing begins.
Apply it
A patient with panreactive warm autoantibody has not been recently transfused and has sufficient usable red cells. Consider autoadsorption to reduce autoantibody interference, then investigate the adsorbed plasma for clinically significant alloantibodies.
Common pitfall: Autologous sample labeling does not guarantee a purely autologous red-cell population. Recent donor cells can make autoadsorption remove clinically significant alloantibodies unintentionally.
38.How does differential alloadsorption preserve an alloantibody, and what can it miss?
Alloadsorption is appropriate when recent transfusion, including within the preceding three months, or insufficient patient cells makes autoadsorption unsuitable. Divide plasma into aliquots and adsorb each with characterized cells selected to leave common alloantibodies in at least one supernatant. R1R1, R2R2, and rr cells provide useful Rh contrasts; complementary Jk(a+b−) and Jk(a−b+) adsorbers preserve Kidd specificities in different aliquots. Pretreatment can remove susceptible targets, but Rh and Kidd antigens remain relevant to cell selection. An antibody against an antigen present on every adsorbing cell may be removed from every aliquot. Consequently, all negative adsorbed panels cannot exclude antibodies to high-prevalence antigens shared by all adsorbers.
Apply it
Suppose plasma contains a warm autoantibody plus alloanti-e. After adequate adsorption, R1R1 and rr cells, which express e, remove both the autoantibody and anti-e. R2R2 cells lack e, so their aliquot loses the autoantibody but preserves anti-e. Testing that supernatant against an appropriate panel reveals e-dependent reactivity. Interpret every aliquot with its documented antigen profile. A separate antibody to a high-prevalence antigen carried by all three adsorbers could disappear from all three supernatants and remain undetected.
Common pitfall: The nonreactive aliquots in this example do not contradict anti-e in the R2R2-adsorbed aliquot; their adsorbers removed its target-specific antibody. Universal nonreactivity after alloadsorption has a high-prevalence-antigen limitation.
Learn Serology: Introduction · Guidelines-for-transfusion-and-immunohaematology-laboratory-practice-2nd-Edition-Revised-September-2026-PUBLISHED-1.pdf
39.What does an eluate add to a red-cell sensitization investigation?
Elution releases antibody from sensitized red cells so the recovered material can be tested for reactivity and specificity. It therefore examines cell-bound antibody rather than simply repeating the plasma screen. In a recently transfused patient, an eluate may help investigate antibody associated with a circulating donor-cell population. Results remain dependent on the elution method, adequate washing, and the antigen targets tested. An eluate pattern contributes to a mechanism but must still be correlated with hemolysis and clinical history.
Apply it
After transfusion, a patient develops a positive DAT and unexplained anemia. Compare eluate reactivity with donor antigen information and plasma findings to assess whether a specific antibody has coated transfused cells in the circulation.
Common pitfall: A positive eluate does not quantify red-cell destruction. Its diagnostic value lies in identifying bound reactivity and connecting it to the patient's clinical and transfusion findings.
40.Why does DTT treatment create a Kell-related blind spot?
Anti-CD38 therapy can cause broad reactivity in indirect antiglobulin testing because CD38 is present on reagent red cells. Dithiothreitol treatment can reduce this interference, but it also destroys Kell antigens and affects other susceptible targets. A negative DTT-treated screen therefore does not establish absence of anti-K. The AABB mitigation approach includes K-negative red cells unless the patient is known to be K positive. Treatment history, baseline antigen information, and reagent limitations must remain linked throughout interpretation.
Apply it
A patient receiving anti-CD38 therapy has a nonreactive DTT-treated antibody screen and unknown K status. Select K-negative red cells under the mitigation strategy rather than interpreting the treated screen as exclusion of anti-K.
Common pitfall: Removing drug interference does not restore every antigen target. The same reagent that clarifies one problem can create an antibody-detection gap that requires compensatory selection.
AABB Association Bulletin #16-02 — Mitigating Anti-CD38 Interference
41.When is molecular typing more informative than current serologic phenotyping?
Serologic phenotyping measures antigens on the red cells actually present in the specimen. Recent transfusion can produce a mixed population, and antibody coating may interfere with some typing methods. Molecular testing can help infer the patient's antigen profile when those conditions limit direct phenotyping. However, genotype predicts expression within the assay's coverage and biological assumptions; it is not a universal substitute for every serologic investigation. Transplant history and other causes of mixed genetic material also require consideration.
Apply it
A recently transfused patient needs an extended antigen profile, but current red-cell phenotyping may include donor cells. Consider an appropriately interpreted molecular study, incorporating transplant history and assay coverage, rather than assuming the mixed serologic result is the patient's phenotype.
Common pitfall: A molecular result is not unlimited antigen proof. Rare variants, assay coverage, and mixed genetic populations can affect how confidently genotype predicts the clinically relevant phenotype.
ANZSBT Guidelines for Transfusion and Immunohaematology Laboratory Practice — June 2025 · University of Toronto LearnSerology — Eluate Testing
42.How should serial antibody titers be compared?
A titer is an endpoint measurement under defined assay conditions, not an absolute antibody concentration independent of method. Cell antigen expression, technique, incubation, reading criteria, and reagent changes can alter the endpoint. Serial interpretation therefore requires methodological consistency and appropriate comparison of samples. A reported increase is meaningful only after considering analytical variation and the antibody's clinical context. Do not equate every small endpoint difference with a proportional biological increase or a universal change in clinical risk.
Apply it
Two prenatal antibody titers differ, but they were performed with different techniques and reagent cells. Arrange a comparable assessment before concluding that the change represents a true rise in maternal antibody activity rather than methodological variation.
Common pitfall: A titer is not a universal disease-severity scale. Different antibodies and methods cannot be assigned the same risk solely because they share an endpoint number.
ANZSBT Guidelines for Transfusion and Immunohaematology Laboratory Practice — June 2025
43.When does antibody history restrict electronic crossmatching?
Electronic crossmatching relies on validated information-system rules and an appropriate patient testing history rather than direct serologic testing of each donor-recipient combination. A current negative antibody screen alone is insufficient when a clinically significant alloantibody has previously been documented. Historical antibodies remain relevant because they may become undetectable and recur after exposure. Selection and compatibility testing must therefore follow both current findings and the permanent antibody record. Automation is safe only when its eligibility conditions are correctly satisfied.
Apply it
A patient's current screen is negative, but the record documents clinically significant anti-Jka. Retain antigen-negative selection and the required serologic compatibility pathway rather than enabling electronic crossmatch based only on the current sample.
Common pitfall: Software eligibility should not erase clinical history. A negative current screen cannot by itself authorize electronic crossmatching in a patient with a significant historical alloantibody.
44.How should discordant results across testing platforms be investigated?
Tube, column agglutination, and solid-phase methods differ in sensitivity and susceptibility to interference, so reproducible disagreement requires a testable explanation. Anti-CD38 treatment is one cause of broad IAT reactivity that may differ in strength across methods. A weak alloantibody can also react on one platform while remaining undetectable on another. Compare matched untreated and DTT-treated cells when anti-CD38 interference is suspected: DTT reduces CD38-related reactivity while preserving Rh targets such as e. Valid treatment and detection controls are essential. Disappearance of reactivity then supports drug interference over a detectable antibody to a retained target, while antibodies to DTT-sensitive targets remain unresolved.
Apply it
In a hypothetical case, a patient recently started daratumumab after a negative baseline screen and received red cells six weeks ago. A reliable pretransfusion profile is e negative. All three current screening cells express e and react 1+ by column agglutination, but tube IAT is negative. Identity checks agree, both platforms' weak-positive and negative controls pass, tube check cells react appropriately, and the DAT is negative. Competing explanations are anti-CD38 interference and a weak alloanti-e detected only by the column method. Test a characterized panel containing e-positive and e-negative cells before and after validated DTT treatment. Untreated cells are uniformly reactive; all DTT-treated cells are nonreactive. A weak anti-e control still reacts with treated e-positive cells and not treated e-negative cells, while a Kell control confirms expected loss of its DTT-sensitive target. This supports anti-CD38 interference with no anti-e detected under the tested conditions. The treated negative panel cannot exclude anti-K or other antibodies to destroyed targets; provide K-negative red cells unless reliable K-positive status is established and retain historical antibody requirements.
Common pitfall: A negative tube result or DAT does not by itself resolve column panreactivity. Likewise, disappearance after DTT is not proof that all alloantibodies are absent: treatment removes some of the targets needed to detect them.
AABB Association Bulletin #16-02 — Mitigating Anti-CD38 Interference · ANZSBT Guidelines for Transfusion and Immunohaematology Laboratory Practice — June 2025
Transfusion Practice15–20%
45.How should red-cell transfusion decisions incorporate patient blood management?
For most hemodynamically stable hospitalized adults, the 2023 AABB International Guidelines recommend a restrictive strategy, considering transfusion when hemoglobin is below 7 g/dL (70 g/L). This is a consideration threshold, not an automatic order or a universal target. Assess symptoms attributable to anemia, physiologic reserve, the cause and trajectory of anemia, and alternatives such as iron replacement. Active hemorrhage requires assessment of ongoing loss and perfusion rather than reliance on a single hemoglobin result. Acute coronary syndromes require separate guidance; do not extend this general stable-adult recommendation to them. Source: [2023 AABB International Guidelines](https://clinlab.ucsf.edu/sites/g/files/tkssra15786/files/wysiwyg/RBC%20Transfusion%202023%20AABB%20International%20Guidelines.pdf).
Apply it
A hemodynamically stable hospitalized adult has hemoglobin 6.8 g/dL (68 g/L), iron-deficiency anemia, persistent exertional dyspnea attributed to anemia, no active bleeding, and no acute coronary syndrome. The hemoglobin is below the 7 g/dL consideration threshold, and the symptoms strengthen the case for red-cell transfusion after clinical assessment. Treat the iron deficiency as well, because transfusion does not correct its cause. In an otherwise comparable asymptomatic patient at 7.4 g/dL (74 g/L), cause-directed therapy and monitoring would generally be favored over routine transfusion.
Common pitfall: Neither being below 7 g/dL nor being above it resolves every decision. Symptoms, alternatives, and the relevant patient population matter; active hemorrhage and acute coronary syndromes require separate assessment.
Circular of Information for the Use of Human Blood and Blood Components
46.Why do platelet transfusions require two ABO directions and separate RhD reasoning?
Platelet ABO incompatibility works in two directions. Donor plasma anti-A or anti-B can hemolyze recipient red cells; recipient anti-A or anti-B can clear donor platelets bearing the corresponding ABO antigen, reducing the platelet increment. ABO-identical platelets avoid both mismatches when available. For plasma-incompatible alternatives, low-titer selection, platelet additive solution, or plasma reduction can reduce donor-antibody exposure. Platelets do not express RhD, but residual donor red cells can cause D sensitization. Rh immune globulin is a preventive consideration for selected RhD-negative recipients, especially those with childbearing potential; residual-red-cell exposure differs by component type and is generally lower with modern apheresis platelets.
Apply it
A group O recipient given group A platelets may have a reduced increment because recipient anti-A recognizes donor platelet A antigen. A group A recipient given group O platelets instead faces donor anti-A exposure to recipient red cells. Separately, an RhD-negative recipient of childbearing potential receiving RhD-positive platelets warrants assessment for Rh immune globulin, considering whether the component is apheresis-derived or whole-blood-derived and its residual red-cell content.
Common pitfall: Reducing donor plasma addresses donor-antibody exposure; it does not remove donor platelet ABO antigens targeted by recipient antibodies. Rh immune globulin addresses D sensitization and does not correct either ABO mismatch.
Australian Red Cross Lifeblood — Component compatibility · Circular of Information for the Use of Human Blood and Blood Components · Platelet transfusion, alloimmunization and management of platelet refractoriness | Professional Education
47.How is compatible plasma selected for an ABO-typed recipient?
Plasma compatibility is determined principally by antibodies in donor plasma that could attack recipient red cells. For a group A recipient, donor anti-A is the central ABO concern. This reverses the familiar red-cell selection perspective, where recipient antibodies attack donor cells. Plasma should also be ordered for an appropriate factor-replacement indication rather than as routine volume expansion. Keep the clinical indication and compatibility analysis separate: a compatible unit may still be an inappropriate treatment for the patient's actual deficit.
Apply it
A group A patient requires plasma for a clinically relevant multiple-factor deficiency. Compare available products by whether their plasma contains anti-A, then select an appropriate compatible component rather than applying the red-cell emergency selection rule.
Common pitfall: ABO compatibility does not establish clinical indication. Plasma may be compatible with the recipient yet fail to address an isolated deficit as efficiently as a targeted replacement.
Australian Red Cross Lifeblood — Component compatibility · Circular of Information for the Use of Human Blood and Blood Components
48.Which findings support an acute immune hemolytic transfusion reaction?
Acute immune hemolysis is supported by a temporally associated clinical reaction, evidence of red-cell destruction, and a coherent incompatibility investigation. ABO errors are especially dangerous because recipient antibodies can attack transfused donor red cells rapidly. Initial assessment includes stopping the transfusion, verifying identity, and evaluating the patient and implicated component. Fever or hypotension alone is not specific. Compare pretransfusion and posttransfusion findings, including hemolysis evidence and appropriate serologic testing, to distinguish immune injury from bacterial or nonimmune causes.
Apply it
Shortly after red-cell transfusion starts, a patient develops pain, hypotension, and hemoglobinemia. Stop the transfusion, initiate urgent clinical assessment, and reconcile patient, specimen, and component identities while investigating immune and other serious causes.
Common pitfall: A positive DAT alone does not prove the entire reaction mechanism. Conversely, urgent management should not wait for a completed antibody investigation when severe hemolysis is suspected.
49.How is delayed hemolysis distinguished from an inadequate initial response?
A delayed hemolytic transfusion reaction involves red-cell destruction after transfusion, often driven by an anamnestic alloantibody response. A falling hemoglobin, biochemical hemolysis, a new or reappearing antibody, and compatible timing support the diagnosis. Inadequate hemoglobin increment alone is nonspecific because bleeding, dilution, and other processes can produce it. Compare the initial response with subsequent trends and investigate the patient's antibody history. Future support must account for the implicated specificity even if later samples again become nonreactive.
Apply it
A patient initially responds to transfusion but later develops falling hemoglobin, increased bilirubin, and reappearance of a historical antibody. Investigate delayed immune destruction rather than attributing the entire pattern to an insufficient number of units.
Common pitfall: A poor increment is not synonymous with immune hemolysis. Establish red-cell destruction and connect the antibody to an antigen exposure before assigning the reaction mechanism.
Australian Red Cross Lifeblood — Delayed haemolytic transfusion reactions
50.Which clues favor TACO in posttransfusion respiratory distress?
Transfusion-associated circulatory overload produces respiratory compromise through hydrostatic pulmonary edema associated with circulatory overload. Supporting findings include fluid accumulation, cardiovascular changes, hypertension, and other evidence of increased filling pressure. The patient's reserve and the rate and volume of administration matter. Compare these findings with alternative causes of pulmonary edema, particularly TRALI. Bilateral infiltrates and hypoxemia are shared features, so they do not independently identify the mechanism. The discriminating question is whether circulatory overload substantially explains the respiratory deterioration.
Apply it
A patient with limited cardiac reserve develops dyspnea, hypertension, elevated venous pressure, and positive fluid balance during transfusion. Prioritize an overload assessment while the transfusion is stopped and urgent clinical management addresses the respiratory deterioration.
Common pitfall: Posttransfusion hypoxemia is not automatically TRALI. Evidence of circulatory overload and cardiovascular stress can make hydrostatic edema the more coherent explanation for otherwise similar imaging.
Australian Red Cross Lifeblood — Transfusion-associated circulatory overload
51.Which clues favor TRALI over circulatory overload?
Transfusion-related acute lung injury presents with acute hypoxemia and bilateral pulmonary edema during or within six hours of transfusion when hydrostatic overload does not primarily explain the edema. Pulmonary endothelial injury and inflammatory cell activation are central mechanisms; donor leukocyte antibodies can contribute but are not required to recognize the clinical syndrome. Assess other acute lung injury risks and the pretransfusion respiratory trajectory. The diagnosis depends on the full clinical pattern, not a positive donor antibody result alone.
Apply it
A previously stable patient develops severe hypoxemia and bilateral edema two hours after transfusion, without evidence of circulatory overload. Investigate TRALI and competing causes while arranging respiratory support and transfusion-service review of the implicated components.
Common pitfall: A negative donor leukocyte-antibody investigation does not automatically exclude TRALI. Clinical criteria and the edema mechanism remain central because antibody demonstration is not universally required.
Australian Red Cross Lifeblood — Transfusion-related acute lung injury
52.How should suspected transfusion-transmitted bacterial infection be investigated?
Severe fever, rigors, hypotension, or shock during transfusion should raise concern for bacterial contamination as well as other serious reactions. Investigation requires recipient blood cultures and culture of the implicated component, with preservation of the bag and administration set according to procedure. Related components may need to be located and held. Demonstrating a matching organism strengthens attribution, but urgent patient assessment and treatment cannot await final culture results. An apparently normal component does not exclude contamination.
Apply it
A patient develops rigors and shock during platelet transfusion. Stop the transfusion, notify the clinical and transfusion teams, obtain recipient cultures, retain the component for culture, and identify related products while urgent sepsis treatment proceeds.
Common pitfall: Do not discard the implicated bag after stopping transfusion. Losing the component can prevent microbiologic comparison and delay identification of other products from the same donation.
Australian Red Cross Lifeblood — Transfusion-transmitted bacterial infection
53.When is a febrile nonhemolytic reaction a defensible interpretation?
Febrile nonhemolytic transfusion reactions can involve recipient responses to leukocyte antigens or inflammatory mediators associated with the component. However, fever during transfusion is also compatible with hemolysis, bacterial contamination, or an unrelated illness. The benign-sounding label is therefore appropriate only after assessment of serious alternatives. Reaction severity, accompanying symptoms, identity checks, hemolysis testing, and cultures when indicated guide the distinction. Leukocyte reduction lowers some febrile reaction risk but does not make fever during transfusion automatically benign.
Apply it
A patient develops fever and chills during transfusion without an immediately obvious cause. Stop and assess the reaction, then investigate hemolysis or contamination as indicated before concluding that the event is a febrile nonhemolytic reaction.
Common pitfall: Improvement after an antipyretic does not establish the mechanism. A serious reaction can temporarily improve while the underlying incompatibility or infectious process remains clinically important.
54.How do apheresis procedures create mechanism-specific risks?
Apheresis separates and removes or collects selected blood constituents while returning others. Risks depend on the extracorporeal circuit, anticoagulant, removed material, replacement fluid, and the patient's physiology. Citrate exposure can reduce ionized calcium, whereas volume shifts and removal of plasma constituents create different concerns. Identify which part of the procedure explains the observed change rather than grouping every symptom as an allergic reaction. Plasma exchange removes coagulation proteins along with the intended circulating target; albumin replacement supplies volume but does not replace those factors.
Apply it
After repeated plasma exchanges with albumin replacement, a patient develops a substantial fibrinogen decline before an invasive procedure. Connect the trend to removal of plasma proteins without equivalent factor replacement. Review bleeding risk, exchange timing, fibrinogen and other coagulation findings, and the replacement strategy. This pattern requires assessment of factor depletion rather than an HPA-antibody investigation or an automatic diagnosis of an allergic reaction.
Common pitfall: Adequate volume replacement does not establish adequate coagulation-factor replacement. Conversely, choosing plasma changes factor replacement and also introduces donor-plasma exposure that must be considered.
Circular of Information for the Use of Human Blood and Blood Components
Laboratory Operations10–15%
55.What must follow a failed quality-control result?
Failed quality control requires investigation, correction, and assessment of potentially affected patient results. Under 42 CFR 493.1282, evaluate patient results from the unacceptable run and since the last acceptable run to determine whether they were adversely affected. Correcting the immediate analyzer or reagent problem is only part of the response. Identify results requiring repeat testing, corrected reports, or clinical communication; document the cause, actions, and restored acceptable performance. CMS QSO-25-10-CLIA provides the updated Appendix C guidance for this requirement.
Apply it
A control failure is traced to a deteriorating reagent lot after patient results were released. Evaluate results from the failed run and the interval since the last acceptable run, determine which were affected, repeat or correct reporting as appropriate, and document restored performance before routine reporting resumes.
Common pitfall: A passing repeat control does not retrospectively validate every earlier result. Patient-result review must address the potentially affected interval rather than only the failed control or the newest run.
56.How do engineering controls reduce sharps injuries?
Sharps prevention prioritizes devices and work practices that reduce contact with contaminated needles. Safety-engineered devices, accessible sharps containers, and prompt disposal reduce opportunities for injury. Routine recapping, bending, breaking, or manipulating contaminated needles introduces avoidable exposure. Personal protective equipment complements these controls but does not make unsafe handling acceptable. An effective process places the disposal container where the sharp is used and ensures staff can activate the safety feature without unnecessary additional handling.
Apply it
A collection area requires staff to carry exposed used needles across the room to disposal. Relocate an appropriate sharps container to the point of use and reinforce immediate disposal with the device's safety feature activated.
Common pitfall: Gloves do not prevent needle penetration. Treating protective clothing as a substitute for safer devices and immediate disposal leaves the central injury mechanism unchanged.
OSHA — Bloodborne Pathogens: General Guidance · OSHA Hospital eTool — Needlestick/Sharps Injuries
57.How should competency findings change staffing assignments?
Training records, continuing education, and proficiency-testing success provide useful evidence but do not alone establish competence for every assigned task. Competency assessment combines direct observation of testing and instrument functions, review of result recording and reporting, review of relevant records, challenge-sample performance, and problem solving. Match findings to specific responsibilities. A failure in emergency-release identification or documentation requires correction of that task and reassessment before independent assignment. Staffing plans must maintain qualified coverage while remediation occurs rather than using workload pressure to waive demonstrated performance requirements.
Apply it
A technologist passes routine antibody-identification challenges but omits a required identity check during an emergency-release simulation. Arrange qualified coverage for independent emergency release, provide targeted retraining, and observe successful reassessment of the failed process before restoring that responsibility. Review whether the procedure or staffing conditions also contributed.
Common pitfall: A successful proficiency-testing event cannot demonstrate every aspect of individual competence. Conversely, one defined failure should lead to a documented assessment of affected duties rather than an unsupported assumption that every unrelated skill has failed.
qso-25-10-clia.pdf · ASCP BOC BB/SBB Examination Content Guideline — December 5, 2025
58.How should method evaluation and instrument troubleshooting establish reliable performance?
Before clinical use, define performance criteria for the intended method, including clinically important positive and negative challenges, instrument functions, workflow, and information-system transfer. During operation, a failure should be traced to the part of the system capable of causing it. In tube antiglobulin testing, inadequate cell washing can leave free globulin that neutralizes antiglobulin reagent. A cell washer therefore requires functional assessment of saline delivery, complete cycles, and effective removal of supernatant; a completed cycle display alone does not establish adequate washing. After correction, demonstrate acceptable function and control performance and assess potentially affected results.
Apply it
A new analyzer misses a weak clinically significant antibody despite high overall agreement; investigate that failure against predefined acceptance criteria before approval. In a separate instrumentation problem, several negative tube IATs processed by an automated cell washer also have nonreactive check cells, while a controlled manual repeat is valid. Inspection identifies an obstructed saline line and inadequate wash delivery. Remove the washer from service, correct the obstruction, verify delivery and washing performance, and repeat affected tests using a functioning validated process. Review results since the last documented acceptable performance.
Common pitfall: Passing routine negative samples can conceal a method's detection gap. Likewise, an instrument's completion message does not demonstrate that the required physical process occurred or retrospectively validate affected patient results.
FDA-hosted Package Insert — Anti-Human Globulin Anti-IgG (Rabbit) · qso-25-10-clia.pdf · Guidelines-for-transfusion-and-immunohaematology-laboratory-practice-2nd-Edition-Revised-September-2026-PUBLISHED-1.pdf
59.How should staffing and equipment costs be compared meaningfully?
Compare alternatives over the same period and workload, separating fixed costs from costs that change with test volume. In a hypothetical annual model, method A costs $20,000 + $5N and method B costs $40,000 + $3N, where N is the number of tests. Setting the totals equal gives $2N = $20,000, so the break-even workload is 10,000 tests. Both then cost $70,000 annually. This arithmetic answers the stated model; it does not establish that all staffing, quality, maintenance, backup, or implementation costs have been included.
Apply it
At 5,000 tests, method A costs $45,000 and method B $55,000, so A is $10,000 cheaper. At 15,000 tests, A costs $95,000 and B $85,000, so B is $10,000 cheaper. Before purchasing, test whether peak workload needs extra staff, whether either method needs paid backup capacity, and whether omitted QC, validation, training, service, or downtime costs change the comparison.
Common pitfall: Equal annual volume does not imply equal service capacity. A cheaper average cost can conceal inadequate peak staffing or urgent-test availability, and omitted fixed or variable costs can shift the break-even point.
ASCP BOC BB/SBB Examination Content Guideline — December 5, 2025
60.How does end-to-end traceability support risk management?
Traceability links a product or specimen to its identity, processing, storage, testing, distribution, and final disposition. It supports recalls, reaction investigations, and assessment of temperature or labeling failures. For tissues and blood components, an inventory count alone cannot establish where each item went or which recipient was exposed. Information systems and manual contingencies must preserve this linkage during downtime. Risk management focuses on preventing identity breaks and ensuring that an affected item can be located promptly when new information emerges.
Apply it
A storage failure affects both blood components and managed tissues. Use item-level records to identify remaining stock and distributed items, determine recipient exposure, and document disposition rather than relying on aggregate counts from the affected refrigerator.
Common pitfall: Reconciliation of total quantities does not prove item-level traceability. Correct counts can coexist with the wrong product being assigned to a recipient or storage history.
ASCP BOC BB/SBB Examination Content Guideline — December 5, 2025 · Circular of Information for the Use of Human Blood and Blood Components
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Allocate study across the published SBB ranges, with the greatest sustained attention to Serologic and Molecular Testing and Immunology and Physiology.
- Build antibody investigations around explicit hypotheses: target antigen, informative cells, treatment effects, differential adsorption, high-prevalence-antigen limitations, and the patient's transfusion history.
- Distinguish component modifications by mechanism: leukocyte removal, plasma removal, and donor T-cell inactivation. Interpret component QC measurements against stated product specifications.
- Calculate timed corrected count increments before attributing platelet refractoriness to alloimmunity; investigate immune and nonimmune explanations.
- Practise paired comparisons: red-cell versus plasma compatibility, DAT versus IAT, TACO versus TRALI, and current antibody detection versus historical sensitization.
- Include donor-health qualification and specialist administration: patient-result impact after QC failure, competency-based staffing, instrument function, method evaluation, worked cost comparisons, information systems, inventory, and tissue traceability.
- Extend beyond this selection to every official outline topic, including less common blood groups, alternative complement mechanisms, coagulation assays, donor procedures, instrumentation, and specialized techniques.
A practical preparation plan
1. Map the complete outline
Mark each official SBB topic as explainable, partly understood, or unfamiliar. Include work outside your current role and reserve study time for SBB-only administration.
2. Explain mechanisms before memorizing actions
For each component or assay, state what is removed, detected, inactivated, or replaced. Then identify the clinically important limitation that remains.
3. Work investigations from competing explanations
For discrepancies and panreactivity, write two plausible mechanisms and choose a test that separates them. Track how recent transfusion, medication, and transplantation change interpretation. Use selected antigen contrasts and identify which antibodies each adsorbing cell could remove.
4. Practise calculations with stated assumptions
Calculate dilutions, component yields, corrected count increments, expected compatible-unit yield, and operating costs. Rework the annual cost comparison at 5,000, 10,000, and 15,000 tests. Label units and distinguish independent frequencies, expected yield, and guaranteed availability.
5. Review every alternative in the drills
Answer the 20 questions, then explain why each alternative fails in that specific case. Classify errors as mechanism, interpretation, compatibility, calculation, or quality-system errors.
6. Close gaps with active recall
Use the flashcards to recall the mechanism and its boundary without looking. Revisit weak areas against the complete outline and the relevant clinical or regulatory reference.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ASCP BOC BB/SBB Examination Content Guideline — December 5, 2025
- ASCP BOC BB/SBB Examination Content Guideline — September 25, 2025
- ASCP BOC Content Guidelines & Reading Lists
- Australian Red Cross Lifeblood — Irradiated components
- Australian Red Cross Lifeblood — Cryoprecipitate
- Circular of Information for the Use of Human Blood and Blood Components
- Australian Red Cross Lifeblood — ABO
- Joint Statement on RHD Genotyping for Pregnant Women and Other Females of Childbearing Potential
- Australian Red Cross Lifeblood — Component compatibility
- Vaughan et al. — Inhibition of erythroid progenitor cells by anti-Kell antibodies in fetal alloimmune anemia
- Canadian Blood Services — Neonatal Platelet Investigation – Maternal
- ANZSBT Guidelines for Transfusion and Immunohaematology Laboratory Practice — June 2025
- AABB Association Bulletin #16-02 — Mitigating Anti-CD38 Interference
- University of Toronto LearnSerology — Autoadsorption
- University of Toronto LearnSerology — Eluate Testing
- FDA-hosted Package Insert — Anti-Human Globulin Anti-IgG (Rabbit)
- Canadian Blood Services — Pre-transfusion testing
- Australian Red Cross Lifeblood — Transfusion-associated circulatory overload
- Australian Red Cross Lifeblood — Delayed haemolytic transfusion reactions
- Australian Red Cross Lifeblood — Transfusion-transmitted bacterial infection
- Australian Red Cross Lifeblood — Transfusion-related acute lung injury
- Canadian Blood Services — Transfusion reactions
- CMS — Revised State Operations Manual Appendix C: Survey Procedures and Interpretive Guidelines for Laboratories
- OSHA — Bloodborne Pathogens: General Guidance
- OSHA Hospital eTool — Needlestick/Sharps Injuries
- download
- Platelet transfusion, alloimmunization and management of platelet refractoriness | Professional Education
- qso-25-10-clia.pdf
- Alkaline CPD and the preservation of RBC 2,3-DPG - PubMed
- Adsorption of Lec and Led from plasma onto red blood cells - PubMed
- Induction of red blood cell destruction by graft-derived antibodies after minor ABO-mismatched heart and lung transplantation - PubMed
- K222831.pdf
- Learn Serology: Introduction
- Guidelines-for-transfusion-and-immunohaematology-laboratory-practice-2nd-Edition-Revised-September-2026-PUBLISHED-1.pdf
- Platelet transfusion, alloimmunization and management of platelet refractoriness | Professional Education
- Pre-transfusion testing | Professional Education
- updates-in-red-blood-cell-transfusion-thresholds.pdf
- Federal Register, Volume 80 Issue 99 (Friday, May 22, 2015)
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.